Agnes Artiges

Download as pdf or txt
Download as pdf or txt
You are on page 1of 65

Quality on the move at the EDQM

Lisboa
Lisboa,, 11 October 2004

Dr Agn
s Artiges
Agns
Director
Director,, European Directorate for the Quality of
Medicines - Council of Europe
A. Artiges, Lisbonne, 11/10/2004

Quality is never an accident.


It is always the results of high intention,
sincere effort, intelligent direction and
skillfull execution ; it represents the wise
choice of many options.
John Ruskin

A. Artiges, Lisbonne, 11/10/2004

AGENDA

Partnership European framework


Standardisation Ph. Eur.
Certification of suitability of monographs
for API
European Biological Standardisation
Programme
European OMCLs Network
A. Artiges, Lisbonne, 11/10/2004

EUROPEAN REGULATORY FRAMEWORK

A. Artiges, Lisbonne, 11/10/2004

Partnership EDQM-CoE/EU
EP Convention
1964: EU Observer
1975-2004: EU Dir, Reg. refers to EP
1994: EU signs the Convention
Contracts
1992: Biological standardisation
1994: setting up the Eur. Network of OMCLs
1997: EMEA post marketing control of centrally
authorised products
A. Artiges, Lisbonne, 11/10/2004

MISSIONS OF THE EDQM (1)

SECRETARIAT OF THE PHEUR COMMISSION


Goals of the Pheur:
- Harmonise the Q and the C of medicines for
human and veterinary use in Europe
- Contribute to the protection of Public health
- Promote free movement of medicines in
Europe
Activities based on an international
convention from the Council of Europe
A. Artiges, Lisbonne, 11/10/2004

Secretariat of Ph. Eur. Commission

A. Artiges, Lisbonne, 11/10/2004

Ph. Eur. MEMBER & OBSERVERSHIP


(including EU)

A. Artiges, Lisbonne, 11/10/2004

Purpose of a monograph?
Public standard
Independent evaluation of quality
specification
Applicable by all laboratories
Regulators need uniform quality standard
Sets standard for future products
A. Artiges, Lisbonne, 11/10/2004

The European Pharmacopoeia


Recent development

5th Edition (2004), general monographs


International harmonisation among JP, EP, USP
Functionality-related characteristics in excipient
monographs
Control of impurities in APIs
The Certification scheme
Electronic communication

A. Artiges, Lisbonne, 11/10/2004

10

General monographs 1.1


Cover classes defined by different criteria:
production method, origin, risk factors
Deal with aspects that cannot be treated in
each individual monograph
Residual solvents, polymorphism,
pesticides in herbals, etc.

A. Artiges, Lisbonne, 11/10/2004

11

Scope of monographs
Aim is to cover all sources of a product
approved for use in EP Member States
Monograph does not necessarily cover
other sources
Suitability to be demonstrated (CEP)

A. Artiges, Lisbonne, 11/10/2004

12

Ph. Eur.: Work Programme


Based on inquiries on needs of users
Licensing authorities
Industries, hospitals

Monographs
Pharmeuropa (4 issues/year)
Internet
Scientific seminar
A. Artiges, Lisbonne, 11/10/2004

13

Ph. Eur. and new technologies (1)


Products of Recombinant DNA Technology (5th Edition)
Alternative methods for control of microbiological quality
(Pharmeuropa No 16.4)
Cell & gene Therapy (Pharmeuropa No 16.4)

A. Artiges, Lisbonne, 11/10/2004

14

Ph. Eur. and new technologies (2)

Adenovirus vectors for human use


Plasmid vectors for human use
Poxvirus vectors for human use
Human haematopoietic progenitor cells
Gene transfer medicinal products for human use
Bacterial cells used for the manufacture of plasmid
vectors for human use (5.2.10)
Numeration of CD34 + cells in haematopoietic
products (2.7.23)
Microbiological control of cell therapy products
(2.6.27)
A. Artiges, Lisbonne, 11/10/2004

15

EDQM Laboratory

A. Artiges, Lisbonne, 11/10/2004

16

MISSIONS OF THE EDQM (2)

Publication of the Eur. Pharm. Texts (F+E)

5th Edition, updated 3 times a year (Book, CD-ROM


and Online versions)
A forum: PHARMEUROPA (4 issues per year) &
PHARMEUROPA BIO (2 issues per year) ;
An official guideline: THE LIST OF STANDARD TERMS
(pharmaceutical dosage forms, route of admin, containers) to be used in
MA dossiers (27 languages) ;
Technical guide for elaboration of monographs
A. Artiges, Lisbonne, 11/10/2004

17

5th Edition

A. Artiges, Lisbonne, 11/10/2004

18

Implementation dates
Adoption

Publication

Implementation

5 th Edition

11/2003

July 2004

Jan. 2005

Suppl. 5.1

03/2004

Oct. 2004

April 2005

Suppl. 5.2

06/ 2004

Dec. 2004

July 2005

A. Artiges, Lisbonne, 11/10/2004

19

MISSIONS OF THE EDQM (3)


Producing and distributing
Pharmaceutical RS , Biological RS
described in the standards
More than 1600 reference substances
available

A. Artiges, Lisbonne, 11/10/2004

20

MISSIONS OF THE EDQM (4)


Certification of suitability
of Ph. Eur. monographs
Participating in the European regulatory system by a centralised
evaluation of the quality that the quality of material is suitably
controlled by monograph (API & excipients)
Directives 2001/83/EC, 2003/63/EC & 2001/82/EC

A. Artiges, Lisbonne, 11/10/2004

21

How to demonstrate the suitability of


monographs for a substance ?
Improve up-date and transparency of
monographs
Procedure of centralised evaluation
elaborated with
The licensing authorities in Europe
Recognition of its validity
Industries -> assurance on the protection
of the information provided
Certification of suitability
A. Artiges, Lisbonne, 11/10/2004

22

Certification Unit

A. Artiges, Lisbonne, 11/10/2004

23

The CEP Steering Committee


Chairman of the Eur.Ph. Commission
Chairmen of technical groups
CPMP/CMV (QWP/BioWP/IWP/HPWP)
1 reprsentant enregistrement Etats non UE
1 reprsentant de lEMEA (Inspection)
1 reprsentant EDQM
Chairs of TAB
A. Artiges, Lisbonne, 11/10/2004

24

Certification - Inspection
Applicant to agree to be inspected
Inspection by national inspector + 2nd
from another country + EDQM
2 European inspectors outside Europe
1999 Pilot programme
2001 established inspection
48 sites inspected (18 in 2003, 7 in 2004)
A. Artiges, Lisbonne, 11/10/2004

25

Inspection
Inspection inside and outside Europe
Inspection of
Chemicals including sterile bulk
TSE risk
Manufacturers
Brokers

Authorities notified of issues arising


A. Artiges, Lisbonne, 11/10/2004

26

Certification: benefits

Single assessment
Uniformity of assessment
Replaces Drug Master File
Savings of time and cost
Updating of monographs (impurities)
Revision of monographs (new or
replacement test methods)
A. Artiges, Lisbonne, 11/10/2004

27

MISSIONS OF THE EDQM (5)


The European Biological Standardisation
Programme (BSP)
Goals
The establishment of European working standards;
The development and validation of new analytical
methods;
the validation of alternative methods in the
framework of the 3Rs concept (Refine, Reduce,
Replace animal experiments);
A. Artiges, Lisbonne, 11/10/2004

28

Recent achievements
Viral markers for blood HCVRnA, B19
Testing methods
Standard

Alternative methods

Tetanus
Diphteria/Serological methods
Hormones

Standards

EPO, IGg, Fact VIII/IX IG antiD

Established together with WHO,FDA


A. Artiges, Lisbonne, 11/10/2004

29

MISSIONS OF THE EDQM (6)


The European network of the Official
Medicines Control Laboratories (OMCL
network)
Created in 1994 in close collaboration with the E.U.
Goals of the OMCL network:
To develop exchanges and know-how, facilitate mutual
recognition of controls of national laboratories and
promote the future development of harmonised
common standards and foster further work-sharing.
A. Artiges, Lisbonne, 11/10/2004

30

Definition of OMCL
Public Institution which ONLY performs
laboratory testing for a Competent
Authority, independently from the
manufacturer, for medicinal products,
prior to and/or after marketing for the
general surveillance of medicines in
relation to the safety of human patient
and/or animals

A. Artiges, Lisbonne, 11/10/2004

31

OMCL Network: composition


OMCL Network is composed of public OMCLs and,
when appropriate, representatives of Competent
Authorities
Criteria :
establishing a formal QA System based on ISO
17025
Implementing European Pharmacopoeia
Indepency (see definition)
A. Artiges, Lisbonne, 11/10/2004

32

OMCL Network: objectives


Harmonise the administrative and
technical activities of common interests
Mutual recognition of national quality
control tests
OMCL tests samples of medicinal products
and/or its components to check whether
they comply with the specifications in the
MA application or in official documents
such as Ph Eur or specific guidelines
A. Artiges, Lisbonne, 11/10/2004

33

OMCL Network - Where are we ?


already in place:
Common QA system
Official Control Authorities Batch Release with
formal mutual recognition
Centrally authorised products
true work-sharing

A. Artiges, Lisbonne, 11/10/2004

34

OMCL Network - Quality Assurance


Development and maintenance of QA
system initiated in 1998
Implementation of QA System based on
Commonly agreed standard Iso 17025
Peer review (audit)
Specific procedures
PTS (performance measurements)

A. Artiges, Lisbonne, 11/10/2004

35

OMCL Network - Work-sharing


For techniques that are rarely used or
require on-going use
create centres of expertise
For other products cut costs by work-and
information sharing
for e.g. Mutual Recognition products (MRP)
A. Artiges, Lisbonne, 11/10/2004

36

MJA/MJV Programme
1999 - OMCL Network starts MJV/MJA system to help
each other implementing and maintaining a Quality
System
Standard ISO/IEC 17025 was selected
MJA are intended to evaluate the competence of the
labs in an equivalent way to the External
Accreditation Bodies
MJA/MJV highly appreciated - sharing of technical
knowledge, meeting other experts, independent
evaluation
A. Artiges, Lisbonne, 11/10/2004

37

MJA Process (1)


The interested OMCL makes an Audit request to EDQM Div. IV
5 types of Audit scope:
Blank audit (all elements covered, only recommendations
given)
Initial audit (all elements of ISO 17025 are assessed)
Surveillance audit (only specific topics are covered)
Reassessment audit (every 5 years, all elements covered)
Follow up of non-conformities
Audit team: one or more trained auditors from the OMCL Network +
audit team coordinator from EDQM (+ experts if needed)
Auditors sign a Confidentiality statement prior to the audit
OMCL is requested to send QS documentation for evaluation
A. Artiges, Lisbonne, 11/10/2004

38

MJA Process (2)

Audit Notification sent to the OMCL


Audit plan agreed with the OMCL
Audit check list based on ISO/IEC 17025
requirements
Closing meeting: findings are discussed with
OMCL Management
Draft Audit Report is sent to OMCL for comments
OMCL decides on corrective action + informs
Division IV on its status
When all non-conformities are solved, Div IV
sends a MJA Attestation
A. Artiges, Lisbonne, 11/10/2004

39

Tutorial Scheme
Tutors: qualified experts from the OMCL Network or from EDQM carrying out
tuition in the field of interest
Objective: to coach personnel on QA topics (general, specific,
implementation of the Quality system, etc)
TUTORIAL PROCESS
Interested OMCL makes a QA Tutorial request to EDQM Division IV
Coaching is given in the form of lessons, seminars, discussion groups,etc
Tutorial planning established by Division IV + QA Officer of OMCL
Tutors are bound by confidentiality agreement
Tutorial Report is written on site: topics discussed + recommendations

A. Artiges, Lisbonne, 11/10/2004

40

Proficiency Testing Studies


PTS

A. Artiges, Lisbonne, 11/10/2004

41

Proficiency testing
Proficiency testing is the use of inter-laboratory
comparison for the determination of laboratory
testing or measurement performance
Participation in proficiency testing schemes
provides laboratories with an objective means of
assessing and demonstrating the reliability of the
data they are producing
Use as a complement of the QA system in place as
requested by the standard ISO 17025
A. Artiges, Lisbonne, 11/10/2004

42

Some data

Scheme initiated in 1995 (OMCLs + EP lab)


Open to non OMCL labs since 2000 (2004
bio)
3-4 (bio) & 5-6 (physico-chemical)
studies/year
Average of 13 (bio) and 45 (physicochemical) participants/study
Use of compendial methods: EP, BP& USP
(for finished products only)
A. Artiges, Lisbonne, 11/10/2004

43

Physico-Chemical PTS Studies in 2004

Assay of tablets (UV-VIS)


RELS by HPLC
Water semi-micro determination
Assay of tablets (titration)
Chiral purity of essential oils by GC
Acetic acid in synthetic peptides
A. Artiges, Lisbonne, 11/10/2004

44

Physico-Chemical PTS studies for 2005

Assay of injections (HPLC)


Assay of suppositories (titration)
Residual solvents (GC)
Refractive index
Assay of tablets (HPLC)
Impurity profile
A. Artiges, Lisbonne, 11/10/2004

45

Physico-Chemical PTS programme


with WHO

Contractual collaboration with WHO since 2000


Programmes are run for a 1,5-2 years period
On going programme: 5 studies planned between
July 2004 and June 2006
42 control laboratories of the WHO regional offices
in Asia, Africa, South America, East Europe
Protocol based on IP & using essential medicines

A. Artiges, Lisbonne, 11/10/2004

46

Bio PTS Studies in 2004 (1)

PTS052: Testing human blood (plasma pools) for


contamination with B19 virus DNA by
quantitative Nucleic Acid Amplification (NAT)
1st PTS on topic (testing mandatory since 1/04)
Participation OMCLs and manufacturers
1/2 available test kits not appropriate
==> information of kit manufacturer
feedback to users of EP and regulators
A. Artiges, Lisbonne, 11/10/2004

47

Bio PTS Studies in 2004 (2)


PTS054: Testing human blood (plasma
pools) for contamination with
Hepatitis B RNA by qualitative NAT
Performed 1-2 per year
Significant decrease of number of
failing labs over time
First participation of manufacturers
A. Artiges, Lisbonne, 11/10/2004

48

Future Bio PTS studies 2004-5

PTS063: Endotoxin content of human


heparin preparations
PTS065: Serological potency assay of
acellular pertussis vaccines
HCV-NAT (as PTS054 but other virus
genotypes)
B19 NAT (as PTS052)
Pre-kallikrein activator content of human
albumin preparations
Anti-D immunoglobulin: potency assay
A. Artiges, Lisbonne, 11/10/2004

49

General activities
Market Surveillance Studies
MSS

A. Artiges, Lisbonne, 11/10/2004

50

MSS 2003/2004
MSS017 - Matricaria flower
MSS020 - Aciclovir tablets
MSS021 - Amoxicillin granules and powders
MSS022 - Ibuprofen tablets
MSS023 - Omeprazole tablets and capsules

A. Artiges, Lisbonne, 11/10/2004

51

MSS 2004/2005 (1)


MSS025 - Tablets for which subdivision is authorised
MSS026 - Erythromycin liquid preparations and
erythromycin esters preparations
MSS027 - Equisetum stem
MSS028 - Products containing sulfasalazines
Type of products: tablets / suppositories
Assay and impurity profile
MSS029 - Trimethropim
Control of impurities in API and tablets
A. Artiges, Lisbonne, 11/10/2004

52

EU/EEA EUROPEAN NETWORK OF OMCLs


OCABR
Common approach of batch release

Administrative procedure
39 guidelines product specific
mutual recognition

CAP (centrally authorised products)


Sharing sampling and testing
Reports to EMEA
A. Artiges, Lisbonne, 11/10/2004

53

CAP
Regulation 726/2004 & Sampling
and Testing Programme for
centrally authorised products
article 57r

A. Artiges, Lisbonne, 11/10/2004

54

Objectives of sampling and testing (1)


To supervise the quality of medicinal products
To confirm compliance of the medicinal product placed
on the market with its authorised specifications
To monitor the quality of the finished product in all parts
of the distribution chain throughout the authorised shelflife
To investigate suspected quality defects of CAPs -when
requested
To assist in testing of counterfeits of CAPs -when
requested
A. Artiges, Lisbonne, 11/10/2004

55

Objectives of sampling and testing (2)


To make use of existing systems and resources
To avoid duplication`
Provide for work sharing
Mutual recognition of testing results in the EEA

A. Artiges, Lisbonne, 11/10/2004

56

Organisational challenges
Partnership with EMEA/EDQM for cooperation with OMCL network
Support of GMP inspectors through ad hoc
GMP inspectors group
Dedicated EMEA staff member appointed
EDQM strenghtens coordination team
Regular feedback through Advisory Group
A. Artiges, Lisbonne, 11/10/2004

57

EMEA responsibilities
Responsible for choice of medicinal products
- adopted by scientific committees
Liaison with (co) rapporteur/working parties
Communication with Marketing Autorisation
holder
Co-ordination of communication of follow-up
measures
Overall responsibility
A. Artiges, Lisbonne, 11/10/2004

58

EDQM responsibilities

Coordination of EEA OMCL network


Organisation of QA system
Coordination sampling and testing
Receipt and reviewing of documentation
Reference material and specific reagent request
Define sampling and select inspectorates
Provide samples to selected OMCLs
Review and summaries results, report to EMEA
A. Artiges, Lisbonne, 11/10/2004

59

MAH responsibilities

Provision of documentation
Clarification of issues
Supplies of reference material/reagents
Pay for samples through voucher system
Explaining deviations
Implementing necessary follow-up
measures
A. Artiges, Lisbonne, 11/10/2004

60

National Authority Responsabilities


As (cooo) rapporteur/assessor - selection
of test and advising on implications of
outcome for dossier
As inspectors, sampling and taking into
account results in national inspection
programmes
As OMLC members, performing tests and
advising on outcomes
A. Artiges, Lisbonne, 11/10/2004

61

Examples of findings (1)


Products within specification limits
In some cases, difficulties in setting up the
test protocols
Problems in method transfer
Difficulty to fulfil system suitability criteria
Unclear descriptions in test methods
Incorrect or missing formulas for calculations
A. Artiges, Lisbonne, 11/10/2004

62

Examples of findings (2)


Questioning method sensitivity, precision
and robustness
Unclear specifications and impurity limits
Discrepancies between specifications and
referring analytical procedures

A. Artiges, Lisbonne, 11/10/2004

63

Origin of samples
Routine GMP-inspection of a contract
manufacturer
Observation of a major GMP-deficiency due
to insufficient testing of incoming APIs
Sampling of the API & Bulk and finished
product for analysis in OMCL
A. Artiges, Lisbonne, 11/10/2004

64

Conclusions
Working in a network: the 3C
Consultation
Collaboration
Co-ordination

A. Artiges, Lisbonne, 11/10/2004

65

You might also like